This is, 48% of APC wild-type tumours were BRAF mutated in the bevacizumab treatment arm, whereas in the cetuximab treatment arm, only 29% were BRAF mutated (p = 0.13, Fisher’s exact test). The gene discussed is APC; the disease is neoplasm.